This activity already occurred and is no longer available.
Monograph: Managing Established Diabetes with Comorbid Conditions: Safe and Effective Treatment Goals and Therapeutic Strategies
This activity outlines treatment options for patients with established diabetes or diabetes of “long-duration” in the older, but not necessarily, elderly population. The eCase Challenge: Managing Established Diabetes with Comorbid Conditions: Safe and Effective Treatment Goals and Therapeutic Strategies is approved for Category 1 Self-assessment CME credit.

Managing Established Diabetes with Comorbid Conditions: Safe and Effective Treatment Goals and Therapeutic Strategies

Lawrence Herman, MPA, PA-C, DFAAPA; Jill Ellis, MPAS, PA-C; Lauren Wieme, MPAS, PA-C

There are almost 29 million Americans with diabetes in the United States. Each year approximately 1.7 million persons are diagnosed with diabetes. This means there are at least 27 million patients with established diabetes, at least 26% of them aged 65 years of age or older, suggesting diabetes of long-duration.

Patients with established or long-duration type 2 diabetes mellitus can be clinically challenging to treat because these patients often lack sufficient beta-cell function to respond to some glucose-lowering agents, may have profound comorbidities, and may have renal impairment that limits the use of traditional agents. This constellation of complications, coupled with the older age of this patient population, dramatically increases the risk of hypoglycemia, which can be a major barrier to treatment success.

Educational Objectives

At the conclusion of this activity, the PA should be better able to:
  • Individualize glycemic treatment goals in patients with established diabetes and existing comorbidities.
  • Use treatment options to balance glycemic control with a low risk of hypoglycemia during treatment intensification efforts.
  • Identify common CV risk comorbidities in patients with diabetes and address CV risk factors according to current treatment recommendations.
  • Choose or adjust antihyperglycemic therapies based on monitoring of older patients’ level of renal function to avoid adverse effects, including hypoglycemia.
  • Follow treatment recommendations from major medical societies when intensifying therapies for glycemic control.

Accreditation Statement

This activity has been reviewed and is approved for a maximum of 1.0 AAPA Category 1 CME credit by the PA Review Panel. Participants should only claim credit commensurate with their participation in the CME activity. This program was planned in accordance with AAPA’s CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs. Approval is valid until May 31, 2017.

Responsibility Statement

AAPA takes responsibility for the content, quality, and scientific integrity of this CME activity.

Disclosure Policy Statement

It is the policy of AAPA to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member has with the commercial interest of any commercial product discussed in an educational presentation. The participating faculty reported the following:

Lawrence Herman, MPA, PA-C, DFAAPA
Moderator
Dean and Professor
College of Health Sciences
PA Studies
Gardner-Webb University
Boiling Springs, North Carolina
Consultant – Novo Nordisk, Regeneron, Sanofi

Jill Ellis, MPAS, PA-C
PAS Faculty Member
Assistant Professor
PA Studies
Grand Valley State University
Grand Rapids, Michigan
No relationship with any commercial interests whose products or services may be mentioned during this presentation.

Lauren Wieme, MPAS, PA-C
Evans Medical Group
Augusta, Georgia
No relationship with any commercial interests whose products or services may be mentioned during this presentation.

Activity Planners

Michael Speidel, Medical Logix, LLC and Katherine Mann, PharmD, have no relationship with any commercial interests whose products or services may be mentioned during this presentation.

AAPA Staff Activity Planners

Daniel Pace and Jennifer Williams have no relationship with any commercial interests whose products or services may be mentioned during this presentation.

Off-Label/Unapproved Product(s) Discussion

Lauren Wieme – degludec/liraglutide; glargine/lixisenatide

Disclaimer

The opinions and comments expressed by faculty and other experts, whose input is included in this program, are their own. This enduring material is produced for educational purposes only. Please review complete prescribing information of specific drugs mentioned in this program including indications, contraindications, warnings, and adverse effects and dosage before administering to patients.

Supported by independent educational grants from Lilly, Merck and Novo Nordisk. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

AAPA offers no returns or refunds on online internet CME activities purchased through our store. All sales are final. Meeting and workshop registrations will be refunded in accordance with the cancellation policy of the meeting and/or workshop, as outlined at registration.



Type:     Internet Activity (Enduring Material)
2557 Registered Users